JP6550053B2 - 腫瘍を治療するための抗ｂ７−ｈ１抗体 - Google Patents

腫瘍を治療するための抗ｂ７−ｈ１抗体 Download PDF

Info

Publication number
JP6550053B2
JP6550053B2 JP2016542315A JP2016542315A JP6550053B2 JP 6550053 B2 JP6550053 B2 JP 6550053B2 JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016542315 A JP2016542315 A JP 2016542315A JP 6550053 B2 JP6550053 B2 JP 6550053B2
Authority
JP
Japan
Prior art keywords
medi
tumor
binding fragment
patient
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016542315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530323A (ja
JP2016530323A5 (enExample
Inventor
ナーワル，ラジェッシュ
フェアマン，デーヴィッド
ロビンズ，ポール
リャン，メイナ
シュナイダー，エイミー
チャベス，カルロス
ハール，カリーナ
パク，ミン
ル，ホン
レベラット，マーロン
スティール，ケイス
ボウトリン，アンマリー
シ，リ
ホン，シェンヤン
ヒッグズ，ブランドン
ロスコス，ローリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2016530323A publication Critical patent/JP2016530323A/ja
Publication of JP2016530323A5 publication Critical patent/JP2016530323A5/ja
Application granted granted Critical
Publication of JP6550053B2 publication Critical patent/JP6550053B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016542315A 2013-09-11 2014-09-11 腫瘍を治療するための抗ｂ７−ｈ１抗体 Active JP6550053B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361876509P 2013-09-11 2013-09-11
US61/876,509 2013-09-11
US201461971212P 2014-03-27 2014-03-27
US61/971,212 2014-03-27
US201461978401P 2014-04-11 2014-04-11
US61/978,401 2014-04-11
US201462003349P 2014-05-27 2014-05-27
US62/003,349 2014-05-27
PCT/EP2014/069425 WO2015036499A1 (en) 2013-09-11 2014-09-11 Anti-b7-h1 antibodies for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019081639A Division JP2019163269A (ja) 2013-09-11 2019-04-23 腫瘍を治療するための抗ｂ７−ｈ１抗体

Publications (3)

Publication Number Publication Date
JP2016530323A JP2016530323A (ja) 2016-09-29
JP2016530323A5 JP2016530323A5 (enExample) 2017-10-12
JP6550053B2 true JP6550053B2 (ja) 2019-07-24

Family

ID=51570487

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016542315A Active JP6550053B2 (ja) 2013-09-11 2014-09-11 腫瘍を治療するための抗ｂ７−ｈ１抗体
JP2019081639A Pending JP2019163269A (ja) 2013-09-11 2019-04-23 腫瘍を治療するための抗ｂ７−ｈ１抗体
JP2020152079A Active JP7119037B2 (ja) 2013-09-11 2020-09-10 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2022021883A Active JP7342167B2 (ja) 2013-09-11 2022-02-16 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2023139429A Pending JP2023166474A (ja) 2013-09-11 2023-08-30 腫瘍を治療するための抗ｂ７－ｈ１抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019081639A Pending JP2019163269A (ja) 2013-09-11 2019-04-23 腫瘍を治療するための抗ｂ７−ｈ１抗体
JP2020152079A Active JP7119037B2 (ja) 2013-09-11 2020-09-10 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2022021883A Active JP7342167B2 (ja) 2013-09-11 2022-02-16 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2023139429A Pending JP2023166474A (ja) 2013-09-11 2023-08-30 腫瘍を治療するための抗ｂ７－ｈ１抗体

Country Status (19)

Country Link
US (3) US10336823B2 (enExample)
EP (2) EP3656398A1 (enExample)
JP (5) JP6550053B2 (enExample)
KR (5) KR20240056664A (enExample)
CN (2) CN105873606B (enExample)
AU (3) AU2014320343B2 (enExample)
BR (1) BR112016005303A2 (enExample)
CA (1) CA2923499A1 (enExample)
DK (1) DK3043816T3 (enExample)
ES (1) ES2749744T3 (enExample)
HU (1) HUE046674T2 (enExample)
IL (5) IL292193B2 (enExample)
MX (1) MX370818B (enExample)
NZ (2) NZ757060A (enExample)
PL (1) PL3043816T3 (enExample)
RU (1) RU2701327C2 (enExample)
SA (1) SA516370713B1 (enExample)
TW (1) TWI643633B (enExample)
WO (1) WO2015036499A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CN105873606B (zh) * 2013-09-11 2020-12-29 米迪缪尼有限公司 用于治疗肿瘤的抗b7-h1抗体
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
DK3149042T3 (da) 2014-05-29 2019-11-04 Spring Bioscience Corp PD-L1-antistoffer og anvendelser deraf
US20160031990A1 (en) * 2014-05-29 2016-02-04 Medlmmune, Llc Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
US20170275347A1 (en) * 2014-09-05 2017-09-28 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
RU2017136709A (ru) * 2015-04-23 2019-05-23 Медиммьюн Лимитед Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr
IL255312B (en) * 2015-05-12 2022-08-01 Genentech Inc Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
EP3668876B1 (en) 2017-08-18 2024-01-24 Cothera Bioscience, Inc. Polymorphic form of tg02
WO2019152743A1 (en) * 2018-01-31 2019-08-08 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
BR112020019116A2 (pt) * 2018-03-22 2021-01-12 Keires Ag Proteínas de ligação, ácido nucleico, vetor, célula hospedeira, método de produção, proteína de ligação, composição farmacêutica e kit
BR112021014112A2 (pt) 2019-01-18 2021-10-13 Dracen Pharmaceuticals, Inc. Usos de composto pró-fármaco de don e inibidor de ponto de controle imunológico para tratar câncer, bem como composto e composição farmacêutica compreendendo o mesmo
JP7582952B2 (ja) * 2019-01-25 2024-11-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 腫瘍治療用の併用医薬組成物
AU2020248002A1 (en) 2019-03-26 2021-10-21 The Regents Of The University Of Michigan Small molecule degraders of STAT3
US12570679B2 (en) 2019-03-29 2026-03-10 Regents Of The University Of Michigan STAT3 protein degraders
US20220265590A1 (en) 2019-06-12 2022-08-25 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
AU2020291464A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
KR20220026575A (ko) * 2019-06-25 2022-03-04 시티 오브 호프 Pdl1 양성 nk 세포 암 치료
BR112021026334A2 (pt) 2019-06-27 2022-05-10 Medstar Health Macrófagos ativados por hdac6, composições, e usos dos mesmos
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
US20220388978A1 (en) 2019-08-27 2022-12-08 Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
CN115023267A (zh) 2019-09-19 2022-09-06 密歇根大学董事会 螺环雄激素受体蛋白质降解剂
WO2021057836A1 (en) * 2019-09-25 2021-04-01 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2021195481A1 (en) 2020-03-26 2021-09-30 The Regents Of The University Of Michigan Small molecule stat protein degraders
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
CN116601140A (zh) 2020-10-02 2023-08-15 羿尊生物医药股份有限公司 用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
TW202304458A (zh) * 2021-03-26 2023-02-01 瑞典商阿斯特捷利康公司 用於黑色素瘤之組合治療
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
WO2009089149A1 (en) * 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN101693562A (zh) * 2009-10-21 2010-04-14 山东大学 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂
NO2504364T3 (enExample) 2009-11-24 2018-01-06
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN105873606B (zh) * 2013-09-11 2020-12-29 米迪缪尼有限公司 用于治疗肿瘤的抗b7-h1抗体
EP3142751B1 (en) * 2014-05-13 2019-08-07 MedImmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US20170275347A1 (en) * 2014-09-05 2017-09-28 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy
US20170320954A1 (en) * 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
BR112018071287A2 (pt) * 2016-04-25 2019-02-19 Medimmune, Llc composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4
CA3022636A1 (en) * 2016-05-13 2017-11-16 Medimmune, Llc Cd40l-fc fusion polypeptides and methods of use thereof

Also Published As

Publication number Publication date
US20210171639A1 (en) 2021-06-10
JP7119037B2 (ja) 2022-08-16
RU2016113341A (ru) 2017-10-16
AU2024203898A1 (en) 2024-07-04
JP2022065100A (ja) 2022-04-26
IL274462A (en) 2020-06-30
US20190338033A1 (en) 2019-11-07
JP2021006537A (ja) 2021-01-21
WO2015036499A1 (en) 2015-03-19
KR20240056664A (ko) 2024-04-30
CN112546217B (zh) 2025-04-29
JP2023166474A (ja) 2023-11-21
EP3043816B1 (en) 2019-08-14
US11827706B2 (en) 2023-11-28
KR20210143932A (ko) 2021-11-29
KR20160044030A (ko) 2016-04-22
JP2016530323A (ja) 2016-09-29
PL3043816T3 (pl) 2020-03-31
TW201605472A (zh) 2016-02-16
EP3656398A1 (en) 2020-05-27
MX370818B (es) 2020-01-08
IL313188B1 (en) 2025-08-01
JP7342167B2 (ja) 2023-09-11
AU2020223728B2 (en) 2024-03-07
CN105873606B (zh) 2020-12-29
AU2020223728A1 (en) 2020-09-17
NZ757060A (en) 2022-07-01
NZ718821A (en) 2022-07-01
IL292193B1 (en) 2024-07-01
BR112016005303A2 (pt) 2017-09-12
IL244422A0 (en) 2016-04-21
RU2701327C2 (ru) 2019-09-25
IL321966A (en) 2025-09-01
US10829557B2 (en) 2020-11-10
CN105873606A (zh) 2016-08-17
US10336823B2 (en) 2019-07-02
KR20220162843A (ko) 2022-12-08
US20160222120A1 (en) 2016-08-04
SA516370713B1 (ar) 2019-03-10
AU2014320343A1 (en) 2016-04-21
IL313188B2 (en) 2025-12-01
IL292193B2 (en) 2024-11-01
DK3043816T3 (da) 2019-10-14
AU2014320343B2 (en) 2020-05-28
JP2019163269A (ja) 2019-09-26
HUE046674T2 (hu) 2020-03-30
RU2019128452A (ru) 2019-10-24
KR102329584B1 (ko) 2021-11-22
EP3043816A1 (en) 2016-07-20
RU2016113341A3 (enExample) 2018-05-30
IL292193A (en) 2022-06-01
KR102661249B1 (ko) 2024-04-25
TWI643633B (zh) 2018-12-11
IL313188A (en) 2024-07-01
KR20260008188A (ko) 2026-01-15
ES2749744T3 (es) 2020-03-23
IL244422B (en) 2020-05-31
IL274462B (en) 2022-05-01
MX2016002826A (es) 2016-09-13
CN112546217A (zh) 2021-03-26
CA2923499A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
JP7342167B2 (ja) 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2017517525A (ja) Ｈｐｖ陰性がんの治療のためのｐｄｌ−１およびｐｄ−１のアンタゴニスト
US20240150469A1 (en) Anti-b7-h1 antibodies for treating tumors
HK40030575A (en) Anti-b7-h1 antibodies for treating tumors
RU2817281C2 (ru) Антитела к b7-h1 для лечения опухолей
HK1224560B (zh) 用於治疗肿瘤的抗b7-h1抗体
HK1226964A1 (en) Anti-b7-h1 antibodies for treating tumors
HK1226964B (en) Anti-b7-h1 antibodies for treating tumors
HK1224560A1 (en) Anti-b7-h1 antibodies for treating tumors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190628

R150 Certificate of patent or registration of utility model

Ref document number: 6550053

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250